Format

Send to

Choose Destination

See 1 citation:

Chem Soc Rev. 2018 Nov 22. doi: 10.1039/c8cs00473k. [Epub ahead of print]

Nanomedicine and macroscale materials in immuno-oncology.

Author information

1
Department of Nanomedicines and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074 Aachen, Germany. tlammers@ukaachen.de yshi@ukaachen.de.
2
Institute of Organic Chemistry, Johannes Gutenberg University, 55099 Mainz, Germany.
3
Department of Pharmaceutics, Ghent University, B-9000 Ghent, Belgium.
4
TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz gGmbH, 55131, Mainz, Germany.
5
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
6
Department of Nanomedicines and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074 Aachen, Germany. tlammers@ukaachen.de yshi@ukaachen.de and Fraunhofer MEVIS, Institute for Medical Image Computing, 52074 Aachen, Germany.
7
Department of Nanomedicines and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074 Aachen, Germany. tlammers@ukaachen.de yshi@ukaachen.de and Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands and Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, 7500 AE Enschede, The Netherlands.

Abstract

Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.

PMID:
30465669
DOI:
10.1039/c8cs00473k

Supplemental Content

Full text links

Icon for Royal Society of Chemistry
Loading ...
Support Center